Prostate cancer

Abstract

Prostate cancer accounts for a quarter of the male cancers managed in a GP’s everyday practice. As GPs are the patient’s primary point of contact, this article will outline when and how to investigate prostate cancer and discuss the ramifications of investigations such as the prostate-specific antigen test. Treatment options, their relative benefits and risks are discussed along with the role of the GP in palliative care, coordinating symptom control and planning for end of life.

Get full access to this article

View all access options for this article.

References

Andriole

G. L.

Crawford

E. D.

Grubb

R. L.

Buys

S. S.

Chia

Church

T. R.

Prorok

P. C.

(2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality results after 13 years of follow-up. Journal of the National Cancer Institute 104(2): 125–132. doi: 10.1016/j.urolonc.2012.08.006.

Cancer Research UK. (2015). Incidence of prostate cancer (2010–2012). Data provided to Cancer Research by Office for National Statistics on request, July 2014. Retrieved from www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#ref-2.

Cary

K. C.

Cooperberg

M. R.

(2013) Biomarkers in prostate cancer surveillance and screening: Past, present, and future. Therapeutic Advances in Urology 5(6): 318–329. doi: 10.1177/1756287213495915.

Chou

Croswell

J. M.

Dana

Bougatsos

Blazina

Lin

(2011) Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine 155(11): 762–771. doi: 10.7326/0003-4819-155-11-201112060-00375.

De Boer, A. G., Taskila, T. K., Tamminga, S. J., Feuerstein, M., Frings-Dresen, M. H., & Verbeek, J. H. (2015). Interventions to enhance return-to-work for cancer patients. Cochrane Database of Systematic Reviews, 2, art. no.: CD007569. doi: 10.1002/14651858.CD007569.pub2.

Eeles

Goh

Castro

Bancroft

Guy

Al Olama

A. A.

Kote-Jarai

(2014) The genetic epidemiology of prostate cancer and its clinical implications. Nature Reviews Urology 11(1): 18–31. doi: 10.1038/nrurol.2013.26.

Epstein

J. I.

Zelefsky

M. J.

Sjoberg

D. D.

Nelson

J. B.

Egevad

Magi-Galluzzi

Klein

E. A.

(2015) A contemporary prostate cancer grading system: A validated alternative to the Gleason score. European Urology 69(3): 428–435. doi: 10.1016/j.eururo.2015.06.046.

Horwitz

E. M.

Bae

Hanks

G. E.

Porter

Grignon

D. J.

Brereton

H. D.

Shipley

W. U.

(2008) Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. Journal of Clinical Oncology 26(15): 2497–2504. doi: 10.1200/JCO.2007.14.9021.

Humphrey

P. A.

(2004) Gleason grading and prognostic factors in carcinoma of the prostate. Modern Pathology 17(3): 292–306.

10.

James

N. D.

Sydes

M. R.

Mason

M. D.

Clarke

N. W.

Dearnaley

D. P.

Spears

M. R.

Parmar

M. M. K.

(2015) Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology 33(suppl; abstr 5001): Retrieved from http://meetinglibrary.asco.org/content/147721-156.

11.

Melia

Moss

Johns

(2004) Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: A cross-sectional study. British Journal of Urology International 94(1): 51–56.

12.

Nam

R. K.

Cheung

Herschorn

Saskin

Klotz

L. H.

Narod

S. A.

(2014) Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: A population-based cohort study. Lancet Oncology 15(2): 223–231. doi: 10.1016/S1470-2045(13)70606-5.

13.

NICE. (2014a). Clinical Guideline175: Prostate cancer: Diagnosis and treatment. Retrieved from www.nice.org.uk/guidance/cg175.

14.

NICE. (2014b). Quality Statement 56: 3 imaging and treatment plans for adults with suspected metastatic spinal cord compression. Retrieved from www.nice.org.uk/guidance/qs56/chapter/quality-statement-3-imaging-and-treatment-plans-for-adults-with-suspected-metastatic-spinal-cord-compression.

15.

NICE. (2015). Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index. Retrieved from nice.org.uk/guidance/dg17.

16.

Patel, A. R., & Klein, E. A. (2009). Risk factors for prostate cancer. Nat Clin Pract Urol, 6(2), 87–95.

17.

Public Health England. (2015). Prostate cancer risk management programme: Overview. Retrieved from https://www.gov.uk/guidance/prostate-cancer-risk-management-programme-overview.

18.

Qureshi

(2011) Prostate cancer screening and the PSA test. InnovAiT 4(9): 509–513.

19.

RCGP. Clinical module 3.07: Men’s health. Retrieved from www.rcgp.org.uk/training-exams/gp-curriculum-overview/online-curriculum/caring-for-the-whole-person/3-07-mens-health.aspx.

20.

RCGP. Clinical module 3.09: End of life care. Retrieved from www.rcgp.org.uk/training-exams/gp-curriculum-overview/online-curriculum/caring-for-the-whole-person/3-09-end-of-life-care.aspx.

21.

Roach

Ceron Lizarraga

T. L.

Lazar

A. A.

(2015) Radical prostatectomy versus radiation and androgen deprivation therapy for clinically localized prostate cancer: How good is the evidence? International Joural of Radiation Oncology Biology Physics 93(5): 1064–1070. doi: 10.1016/j.ijrobp.2015.08.005.

22.

UK National Screening Committee. (2016). The UK national screening recommendation on prostate cancer screening/PSA testing in men over the age of 50. Retrieved from http://legacy.screening.nhs.uk/prostatecancer.

23.

US Preventive Services Task Force. (2012). Prostate cancer: Screening. Retrieved from http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/prostate-cancer-screening.

24.

Wilt

T. J.

Brawer

M. K.

Jones

K. M.

Barry

M. J.

Aronson

W. J.

Fox

Wheeler

(2012) Prostate cancer intervention versus observation trial study. Radical prostatectomy versus observation for localized prostate cancer. New England Journal of Medicine 367(3): 203–213. doi: 10.1056/NEJMoa1113162.

25.

Zlotta

A. R.

Egawa

Pushkar

Govorov

Kimura

Kido

van der Kwast

T. H.

(2013) Prevalence of prostate cancer on autopsy: Cross-sectional study on unscreened Caucasian and Asian men. Journal of National Cancer Institute 105(14): 1050–1058. doi: 10.1093/jnci/djt151. Epub 2013 Jul 11.